Solid-phase assays for the detection of alloantibody against human leukocyte antigens: panacea or Pandora?

Abstract

Serological assessments of antibodies directed against human leucocyte antigens (HLA) formed the basis of early histocompatibility testing (Patel & Terasaki, 1969 N Engl J Med, 280, 735). However, over the past decade, significant advances in HLA antibody detection technologies have emerged. The development and implementation of solid-phase assays has led to safer and more efficient allocation of organs by effectively distinguishing HLA from non-HLA antibodies. Although solid-phase assays are not standardized, they are widely accepted as the new 'gold standard'. However, this technology is not without its challenges. This review is intended to provide a better understanding of solid-phase HLA antibody testing and will focus on important caveats associated with this evolving technology. Examples of the limitations of the technology as well as common data misinterpretations will be shown. Both of which could pose potential harm to transplant recipients (Tait et al., Transplantation, 95, 19).